Investigation of DRD2 and HTR2A mRNA Expression in Two Therapeutic States of Antipsychotic Polypharmacy and Aripiprazole Monotherapy in the Peripheral Blood of Patients With Schizophrenia
Objectives: Schizophrenia is a severe psychiatric disorder that has profound effects on both individuals and the community. Notwithstanding the suggestion for treating schizophrenia with a minimum dose of drugs, antipsychotic polypharmacy increases the patient’s care costs and drug interactions. Ari...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Negah Institute for Scientific Communication
2020-09-01
|
| Series: | Iranian Rehabilitation Journal |
| Subjects: | |
| Online Access: | http://irj.uswr.ac.ir/article-1-1052-en.pdf |
| _version_ | 1797669638573654016 |
|---|---|
| author | Arash Mirabzadeh Hamid Reza Iranpour Hamid Reza Khorram Khorshid Davood Zare-Abdollahi Mehdi Norouzi Venus Vatankhah |
| author_facet | Arash Mirabzadeh Hamid Reza Iranpour Hamid Reza Khorram Khorshid Davood Zare-Abdollahi Mehdi Norouzi Venus Vatankhah |
| author_sort | Arash Mirabzadeh |
| collection | DOAJ |
| description | Objectives: Schizophrenia is a severe psychiatric disorder that has profound effects on both individuals and the community. Notwithstanding the suggestion for treating schizophrenia with a minimum dose of drugs, antipsychotic polypharmacy increases the patient’s care costs and drug interactions. Aripiprazole reduces the metabolic side effects of antipsychotic polypharmacy treatment. DRD2 and HTR2A can serve as predictors for response to treatment in schizophrenic patients. The purpose of this survey was to measure the DRD2 and HTR2A genes expression in the peripheral blood samples using Real-Time Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR).
Methods: A total of 19 patients with a long history of schizophrenia who received at least two types of antipsychotics with daily doses of more than 500 mg of chlorpromazine were entered into the study. The response rates to the treatment based on scores in the Brief Psychiatric Rating Scale (BPRS) questionnaire and DRD2 and HTR2A expression were compared between antipsychotic polypharmacy status and 6 months after monotherapy with aripiprazole.
Results: The levels of DRD2 expression decreased significantly after the intervention. The mean changes in HTR2A expression and the BPRS questionnaire and also the relationship between changes in DRD2 and HTR2A expression and changes in BPRS score after the intervention were not significant.
Discussion: The conversion of the antipsychotic polypharmacy state to monotherapy with aripiprazole has been accompanied by a significant decrease in DRD2A expression. These genes can be used for evaluating the response rate of schizophrenia treatments in the future. |
| first_indexed | 2024-03-11T20:47:23Z |
| format | Article |
| id | doaj.art-658edecec13146f2a2da778f15a4c168 |
| institution | Directory Open Access Journal |
| issn | 1735-3602 1735-3610 |
| language | English |
| last_indexed | 2024-03-11T20:47:23Z |
| publishDate | 2020-09-01 |
| publisher | Negah Institute for Scientific Communication |
| record_format | Article |
| series | Iranian Rehabilitation Journal |
| spelling | doaj.art-658edecec13146f2a2da778f15a4c1682023-10-01T07:16:22ZengNegah Institute for Scientific CommunicationIranian Rehabilitation Journal1735-36021735-36102020-09-01183293300Investigation of DRD2 and HTR2A mRNA Expression in Two Therapeutic States of Antipsychotic Polypharmacy and Aripiprazole Monotherapy in the Peripheral Blood of Patients With SchizophreniaArash Mirabzadeh0Hamid Reza Iranpour1Hamid Reza Khorram Khorshid2Davood Zare-Abdollahi3Mehdi Norouzi4Venus Vatankhah5 Social Determinants of Health Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran. Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran. Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran. Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran. Social Determinants of Health Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran. Imam Khomeini Hospital Complex of Firuzkuh, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Objectives: Schizophrenia is a severe psychiatric disorder that has profound effects on both individuals and the community. Notwithstanding the suggestion for treating schizophrenia with a minimum dose of drugs, antipsychotic polypharmacy increases the patient’s care costs and drug interactions. Aripiprazole reduces the metabolic side effects of antipsychotic polypharmacy treatment. DRD2 and HTR2A can serve as predictors for response to treatment in schizophrenic patients. The purpose of this survey was to measure the DRD2 and HTR2A genes expression in the peripheral blood samples using Real-Time Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR). Methods: A total of 19 patients with a long history of schizophrenia who received at least two types of antipsychotics with daily doses of more than 500 mg of chlorpromazine were entered into the study. The response rates to the treatment based on scores in the Brief Psychiatric Rating Scale (BPRS) questionnaire and DRD2 and HTR2A expression were compared between antipsychotic polypharmacy status and 6 months after monotherapy with aripiprazole. Results: The levels of DRD2 expression decreased significantly after the intervention. The mean changes in HTR2A expression and the BPRS questionnaire and also the relationship between changes in DRD2 and HTR2A expression and changes in BPRS score after the intervention were not significant. Discussion: The conversion of the antipsychotic polypharmacy state to monotherapy with aripiprazole has been accompanied by a significant decrease in DRD2A expression. These genes can be used for evaluating the response rate of schizophrenia treatments in the future.http://irj.uswr.ac.ir/article-1-1052-en.pdfschizophreniapolypharmacyaripiprazoledrd2 genehtr2a gene |
| spellingShingle | Arash Mirabzadeh Hamid Reza Iranpour Hamid Reza Khorram Khorshid Davood Zare-Abdollahi Mehdi Norouzi Venus Vatankhah Investigation of DRD2 and HTR2A mRNA Expression in Two Therapeutic States of Antipsychotic Polypharmacy and Aripiprazole Monotherapy in the Peripheral Blood of Patients With Schizophrenia Iranian Rehabilitation Journal schizophrenia polypharmacy aripiprazole drd2 gene htr2a gene |
| title | Investigation of DRD2 and HTR2A mRNA Expression in Two Therapeutic States of Antipsychotic Polypharmacy and Aripiprazole Monotherapy in the Peripheral Blood of Patients With Schizophrenia |
| title_full | Investigation of DRD2 and HTR2A mRNA Expression in Two Therapeutic States of Antipsychotic Polypharmacy and Aripiprazole Monotherapy in the Peripheral Blood of Patients With Schizophrenia |
| title_fullStr | Investigation of DRD2 and HTR2A mRNA Expression in Two Therapeutic States of Antipsychotic Polypharmacy and Aripiprazole Monotherapy in the Peripheral Blood of Patients With Schizophrenia |
| title_full_unstemmed | Investigation of DRD2 and HTR2A mRNA Expression in Two Therapeutic States of Antipsychotic Polypharmacy and Aripiprazole Monotherapy in the Peripheral Blood of Patients With Schizophrenia |
| title_short | Investigation of DRD2 and HTR2A mRNA Expression in Two Therapeutic States of Antipsychotic Polypharmacy and Aripiprazole Monotherapy in the Peripheral Blood of Patients With Schizophrenia |
| title_sort | investigation of drd2 and htr2a mrna expression in two therapeutic states of antipsychotic polypharmacy and aripiprazole monotherapy in the peripheral blood of patients with schizophrenia |
| topic | schizophrenia polypharmacy aripiprazole drd2 gene htr2a gene |
| url | http://irj.uswr.ac.ir/article-1-1052-en.pdf |
| work_keys_str_mv | AT arashmirabzadeh investigationofdrd2andhtr2amrnaexpressionintwotherapeuticstatesofantipsychoticpolypharmacyandaripiprazolemonotherapyintheperipheralbloodofpatientswithschizophrenia AT hamidrezairanpour investigationofdrd2andhtr2amrnaexpressionintwotherapeuticstatesofantipsychoticpolypharmacyandaripiprazolemonotherapyintheperipheralbloodofpatientswithschizophrenia AT hamidrezakhorramkhorshid investigationofdrd2andhtr2amrnaexpressionintwotherapeuticstatesofantipsychoticpolypharmacyandaripiprazolemonotherapyintheperipheralbloodofpatientswithschizophrenia AT davoodzareabdollahi investigationofdrd2andhtr2amrnaexpressionintwotherapeuticstatesofantipsychoticpolypharmacyandaripiprazolemonotherapyintheperipheralbloodofpatientswithschizophrenia AT mehdinorouzi investigationofdrd2andhtr2amrnaexpressionintwotherapeuticstatesofantipsychoticpolypharmacyandaripiprazolemonotherapyintheperipheralbloodofpatientswithschizophrenia AT venusvatankhah investigationofdrd2andhtr2amrnaexpressionintwotherapeuticstatesofantipsychoticpolypharmacyandaripiprazolemonotherapyintheperipheralbloodofpatientswithschizophrenia |